380 related articles for article (PubMed ID: 17299090)
21. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
Combaret V; Boyault S; Iacono I; Brejon S; Rousseau R; Puisieux A
Mol Cancer; 2008 Jun; 7():50. PubMed ID: 18534018
[TBL] [Abstract][Full Text] [Related]
22. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
Walker AR; Klisovic R; Johnston JS; Jiang Y; Geyer S; Kefauver C; Binkley P; Byrd JC; Grever MR; Garzon R; Phelps MA; Marcucci G; Blum KA; Blum W
Leuk Lymphoma; 2013 Sep; 54(9):1996-2002. PubMed ID: 23256542
[TBL] [Abstract][Full Text] [Related]
24. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.
Powers MV; Clarke PA; Workman P
Cancer Cell; 2008 Sep; 14(3):250-62. PubMed ID: 18772114
[TBL] [Abstract][Full Text] [Related]
25. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
[TBL] [Abstract][Full Text] [Related]
26. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
27. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
Zismanov V; Drucker L; Gottfried M
Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells.
Dong Y; Liang C; Zhang B; Ma J; He X; Chen S; Zhang X; Chen W
Cancer Lett; 2015 May; 361(1):137-46. PubMed ID: 25737303
[TBL] [Abstract][Full Text] [Related]
29. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib as an antitumor agent.
Roccaro AM; Hideshima T; Richardson PG; Russo D; Ribatti D; Vacca A; Dammacco F; Anderson KC
Curr Pharm Biotechnol; 2006 Dec; 7(6):441-8. PubMed ID: 17168660
[TBL] [Abstract][Full Text] [Related]
31. Immune mechanism of the antitumor effects generated by bortezomib.
Chang CL; Hsu YT; Wu CC; Yang YC; Wang C; Wu TC; Hung CF
J Immunol; 2012 Sep; 189(6):3209-20. PubMed ID: 22896634
[TBL] [Abstract][Full Text] [Related]
32. Differential impact of bortezomib on HL-60 and K562 cells.
Kliková K; Štefaniková A; Pilchová I; Hatok J; Chudý P; Chudej J; Dobrota D; Račay P
Gen Physiol Biophys; 2015 Jan; 34(1):33-42. PubMed ID: 25367763
[TBL] [Abstract][Full Text] [Related]
33. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
Richardson PG; Chanan-Khan AA; Lonial S; Krishnan AY; Carroll MP; Alsina M; Albitar M; Berman D; Messina M; Anderson KC
Br J Haematol; 2011 Jun; 153(6):729-40. PubMed ID: 21534941
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Zou P; Kawada J; Pesnicak L; Cohen JI
J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
[TBL] [Abstract][Full Text] [Related]
35. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
Richardson PG; Badros AZ; Jagannath S; Tarantolo S; Wolf JL; Albitar M; Berman D; Messina M; Anderson KC
Br J Haematol; 2010 Aug; 150(4):428-37. PubMed ID: 20618338
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
37. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
38. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
39. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
[TBL] [Abstract][Full Text] [Related]
40. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway.
Shay KP; Wang Z; Xing PX; McKenzie IF; Magnuson NS
Mol Cancer Res; 2005 Mar; 3(3):170-81. PubMed ID: 15798097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]